Dr. Kavitha Bharatham, who leads the computational chemistry team in CCBT, says “Having used Cresset’s software in my previous role, I am very keen to apply it to our work at CCBT. My experience with Forge and Spark makes me confident that they will be valuable tools for our research. The support I have received from Cresset staff has been excellent, and I am very pleased to introduce their computational tools to CCBT for our lead optimization and identification projects. I am confident that we will achieve our goals.” Prof. Ashok Venkitaraman, who directs the CCBT, adds, “The CCBT aims to pioneer innovative new approaches for using chemical tools to understand the biology of human diseases like cancer, and to develop new avenues for therapy. I am pleased that we will be licensing Cresset’s software for our work.”
“We are delighted that the CCBT at inStem has chosen to work with Spark and Forge,” says Dr David Bardsley, Cresset’s Commercial Director. “Spark will enable them to generate novel and diverse structures and to use reagent databases to inform synthetic decisions (http://www.cresset-
Cresset: Sue Peffer, Marketing Manager, Email: sue@cresset-
Cresset develops software for calculating and comparing the molecular field characteristics of chemical compounds. Cresset also offers consultancy services which enable companies to outsource computational chemistry work to achieve high value, on-demand expertise, particularly in the areas of library design, virtual screening, scaffold hopping, lead optimization and patent analysis.
Cresset’s field technology uses the surface properties of molecules to evaluate their activities and properties, rather than relying on 2D structure similarity, which enables Cresset’s users to find more interesting, novel and relevant results than other methods. This field technology provides a smarter, structure independent way of hit-finding, lead switching and lead optimization in drug discovery and other chemistry-based research projects. Cresset’s field technologies have been successfully applied to a very wide range of target classes, with and without structural information, on over 100 projects for major pharmaceutical and biotechnology companies. www.cresset-